MedPath

MEMORY PHARMACEUTICALS

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

5

Active:0
Completed:3

Trial Phases

1 Phases

Phase 2:5

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 2
5 (100.0%)

A Single-Center, Double-Blind (DB) Study of MEM 3454 on P50 Sensory Gating and Mismatch Negativity in Schizophrenia Patients

Phase 2
Conditions
Schizophrenia
Interventions
Drug: Placebo for MEM 3454
First Posted Date
2008-07-31
Last Posted Date
2008-07-31
Lead Sponsor
Memory Pharmaceuticals
Target Recruit Count
12
Registration Number
NCT00725855
Locations
🇺🇸

University of Colorado Health Sciences Center, Denver, Colorado, United States

Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia

Phase 2
Conditions
Cognitive Impairment Associated With Schizophrenia
Interventions
Drug: Placebo for MEM 3454
First Posted Date
2008-01-30
Last Posted Date
2008-12-08
Lead Sponsor
Memory Pharmaceuticals
Target Recruit Count
160
Registration Number
NCT00604760
Locations
🇺🇸

Telecare-Cresta Loma, Lemon Grove, California, United States

🇺🇸

Newport Bay Hospital, Newport Beach, California, United States

🇺🇸

Excell Research, Oceanside, California, United States

and more 40 locations

Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease

Phase 2
Completed
Conditions
Alzheimer's Disease
First Posted Date
2007-04-02
Last Posted Date
2008-05-06
Lead Sponsor
Memory Pharmaceuticals
Target Recruit Count
80
Registration Number
NCT00454870

Safety and Efficacy of MEM 1003 Versus Placebo for the Treatment of Patients With Bipolar I Disorder

Phase 2
Completed
Conditions
Bipolar Disorder With Manic or Mixed Episodes
First Posted Date
2006-09-12
Last Posted Date
2008-05-06
Lead Sponsor
Memory Pharmaceuticals
Target Recruit Count
60
Registration Number
NCT00374920

Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease

Phase 2
Completed
Conditions
Alzheimer's Disease
Interventions
Drug: Placebo for MEM 1003
First Posted Date
2005-11-23
Last Posted Date
2008-05-06
Lead Sponsor
Memory Pharmaceuticals
Target Recruit Count
183
Registration Number
NCT00257673

News

No news found
© Copyright 2025. All Rights Reserved by MedPath